#United States #New York #Class Action #Shareholder Rights #Mereo BioPharma

Mereo BioPharma Group Faces Class Action Lawsuit

On March 10, 2026, The Gross Law Firm announced the filing of a class action lawsuit against Mereo BioPharma Group plc (NASDAQ: MREO). The law firm has released important information for shareholders who purchased shares during a specified class period, which began on June 5, 2023, and ended on December 26, 2025.

Background of the Case

The lawsuit claims that Mereo BioPharma misled investors by providing overly optimistic statements about its operations while concealing significant adverse facts about its clinical trial programs. The Phase 3 ORBIT and COSMIC studies reportedly did not meet their primary endpoints of reducing the annualized clinical fracture rate when compared to control groups. On December 29, 2025, the company confirmed that both studies failed to achieve statistical significance, leading to a sharp decline in the price of Mereo’s American Depositary Shares (ADS). The stock fell dramatically from a closing price of $2.31 on December 26, 2025, to just $0.29 by December 29, marking a staggering drop of over 87.7%.

Allegations

The complaint highlights that while Mereo BioPharma was making positive representations, it was simultaneously hiding critical information regarding the underperformance of the Phase 3 clinical trials. This situation has raised concerns about corporate governance and accountability, as investors were given a false sense of security regarding their investments. Shareholders are encouraged to register and participate in the lawsuit, even if they do not wish to take on the role of lead plaintiff.

Important Deadlines and Steps for Shareholders

For shareholders interested in joining the class action, there is an impending deadline of April 6, 2026. It is essential for affected shareholders to register their information promptly to ensure they are part of this legal pursuit. Once registered, participants will receive updates through a portfolio monitoring service that keeps them informed throughout the lifecycle of the case.

The Gross Law Firm emphasizes that there is no cost or obligation for shareholders to participate in the class action. This initiative represents an opportunity for investors to potentially recover their losses incurred as a result of the alleged misconduct by Mereo BioPharma.

Why Choose The Gross Law Firm?

The Gross Law Firm is a reputable class action law firm, recognized nationally for its commitment to protecting the rights of investors. The firm's mission is to hold companies accountable for deceitful practices and to ensure responsible corporate behavior. With extensive experience in handling class action lawsuits, they strive to recover losses for shareholders who have been misled by companies through fraudulent or negligent actions.

If you believe you may have been affected by these circumstances, reaching out to The Gross Law Firm is a critical step. The firm invites all shareholders who purchased MREO shares within the defined period to contact them and learn more about their rights and options regarding this lawsuit.

Investing in Mereo BioPharma may have had detrimental effects due to the alleged misinformation, but with this class action, affected shareholders have a chance to seek justice and recovery.

Contact Information

For more details or to join the class action, you can contact The Gross Law Firm at:

• - Address: 15 West 38th Street, 12th floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903

Understanding your rights as an investor is crucial, and The Gross Law Firm stands ready to support you in this legal battle against corporate malpractice.